Abstract:G-quadruplex (G4) sequences, which can fold into higher-order G4 structures, are abundant in the human genome and are over-represented in the promoter regions of many genes involved in human cancer initiation, progression, and metastasis. They are plausible targets for G4-binding small molecules, which would, in the case of promoter G4s, result in the transcriptional downregulation of these genes. However, structural information is currently available on only a very small number of G4s and their ligand complexes. This limitation, coupled with the currently restricted information on the G4-containing genes involved in most complex human cancers, has led to the development of a phenotypic-led approach to G4 ligand drug discovery. This approach was illustrated by the discovery of several generations of tri- and tetra-substituted naphthalene diimide (ND) ligands that were found to show potent growth inhibition in pancreatic cancer cell lines and are active in in vivo models for this hard-to-treat disease. The cycles of discovery have culminated in a highly potent tetra-substituted ND derivative, QN-302, which is currently being evaluated in a Phase 1 clinical trial. The major genes whose expression has been down-regulated by QN-302 are presented here: all contain G4 propensity and have been found to be up-regulated in human pancreatic cancer. Some of these genes are also upregulated in other human cancers, supporting the hypothesis that QN-302 is a pan-G4 drug of potential utility beyond pancreatic cancer.

Colchicine Selective Interaction with Oncogene RET G-quadruplex Revealed by NMR.

NMR Studies on the Interaction between Oncogene RET G‐Quadruplex and Berberine †

Solution structure of all parallel G-quadruplex formed by the oncogene RET promoter sequence

Identification of Glycine Receptor Α3 As a Colchicine-Binding Protein.

General Cell-Binding Activity of Intramolecular G-Quadruplexes with Parallel Structure

9,10-Bis[(4-(2-hydroxyethyl)piperazine-1-yl)prop2-yne-1-yl]anthracene: G-Quadruplex Selectivity and Anticancer Activity

A Phenotypic Approach to the Discovery of Potent G-Quadruplex Targeted Drugs

DNA G-quadruplexes as Targets for Natural Product Drug Discovery

G-quadruplex ligands in cancer therapy: Progress, challenges, and clinical perspectives

Mitochondria-Selective Dicationic Small-Molecule Ligand Targeting G-Quadruplex Structures for Human Colorectal Cancer Therapy

Microfluidic-Based G-Quadruplex Ligand Displacement Assay for Alkaloid Anticancer Drug Screening

G-quadruplex stabilization via small-molecules as a potential anti-cancer strategy

Discovery and biological evaluation of 6-aryl-4-(3,4,5-trimethoxyphenyl)quinoline derivatives with promising antitumor activities as novel colchicine-binding site inhibitors

G-Quadruplex binding enantiomers show chiral selective interactions with human telomere

G4-Ligand-Conjugated Oligonucleotides Mediate Selective Binding and Stabilization of Individual G4 DNA Structures

G-quadruplex–R-loop interactions and the mechanism of anticancer G-quadruplex binders

Rational design of small-molecules to recognize G-quadruplexes of c-MYC promoter and telomere and the evaluation of their in vivo antitumor activity against breast cancer

Stabilizing Parallel G-Quadruplex Dna by A New Class of Ligands: Two Non-Planar Alkaloids Through Interaction in Lateral Grooves

Development of a high-contrast fluorescent ligand that targets G-quadruplexes by introducing a triazole rotor onto the dibenzoquinoxaline scaffold

Spectroscopy Probing of the Formation, Recognition, and Conversion of A G-Quadruplex in the Promoter Region of the Bcl-2 Oncogene

Selective stabilization of multiple promoter G-quadruplex DNA by using 2-phenyl-1H-imidazole-based tanshinone IIA derivatives and their potential suppressing function in the metastatic breast cancer